NCT05259813 2023-11-24
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Withdrawn
Clinical Trials
3 trialsNCT04812691 2023-11-22
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Completed
NCT03355859 2019-07-12
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase 1 Unknown